In the investing world, those with superior information usually make the most money. And possibly no group has better information on public companies – and profitably acts on it – than corporate insiders at small-cap biotech and medical technology companies.
RA Capital has outperformed all other healthcare hedge funds over the past decade, based on 13F holdings. In fact, RA's 30.88% annualized return of it's equal-weighted top 20 long portfolio led all other hedge funds over that period. So, when RA manager Peter Kolchinsky discloses portfolio changes,...
Twenty-two minutes after regular market hours closed on July 2, an Orbimed Advisors Form 4 relating to Corvus Pharmaceuticals Inc (CRVS) was posted on the SEC's website. The hedge fund, a 10%+ holder and insider in CRVS, disclosed that between June 27 and July 1 it...
Protagonist Therapeutics insiders bought on Tuesday as their company's stock plummeted after preliminary data appeared to cast doubt on Protagonist's (PGTX) key drug. On Monday, the company presented an initial look at preliminary results from the TRANSCEND Ph2 open-label study of PTG-300 (hepcidin...
Billionaire Mori Arkin filed a 13D on Aclaris Therapeutics (ACRS), a development stage microcap biotech company with a promising treatment for common warts. Arkin bought the shares through his personal partnership, "The 1999 Company." In the activist filing he disclosed the following trades: Purchase/SaleSharesPriceDate Running ...
Solid Biosciences' private placement featured investments by an all star list of top biotech institutional investors. Cambridge-based Solid Biosciences (SLDB) trades at 1/3 of its January 2018 IPO value. But based on the A-list biotech investors buying shares in the company's July 26 $60...
Intra-Cellular Therapies FDA news release on Sept. 10 appeared positive. The FDA informed the company that it will not schedule an Advisory Committee meeting in connection with its review of the company’s new drug application (NDA) for Lumateperone for the treatment of schizophrenia. All good, moving ahead,...
Baupost Group activist filings are rare events. Seth Klarman, the renowned value investor who heads Baupost, prefers to take passive stakes in companies. Since 2006, Baupost has filed 352 passive 13G filings, and made only 25 activist 13D filings, according to data from WhaleWisdom.com.
Engine Capital filed a 13D on Cymabay (CBAY) two weeks after the development stage biotech company halted a trial of its leading drug candidate causing it's shares to fall as much as 75%. In a 13D filing Thursday evening, New York-based Engine Capital, L.P....